Skip to main content
Clinical Trials/CTRI/2021/07/035145
CTRI/2021/07/035145
Not yet recruiting
未知

Validation of Medios AI, an Automated Glaucoma Screening Tool, Deployed Offline, On-The-Edge, on a Smartphone Based Fundus Camera- a prospective Study

Remidio Innovative Solutions Pvt Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Remidio Innovative Solutions Pvt Ltd
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Remidio Innovative Solutions Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Glaucoma Group:Any case of glaucoma with typical glaucomatous disc changes, confirmed by clinical evaluation and visual field test (primary open angle glaucoma(POAG), normal tension glaucoma (NTG), primary angle closure glaucoma (PACG), secondary glaucomas)
  • 2\.Normal Controls (including Ocular hypertension (OHT) and primary angle closure suspects (PACS) status post laser peripheral iridotomy (LPI))
  • 3\.Disc suspects
  • 4\.Reliable Visual field (false positive (FP), false negative (FN) \<20%)

Exclusion Criteria

  • 1\.Patient with acute or sudden vision loss
  • 2\.Patient deemed to have narrow angles on gonioscopy and cannot be dilated (primary angle closure)
  • 3\.Co\-existing retinal pathologies precluding view of disc including Proliferative diabetic retinopathy
  • 4\.Significant media opacity precluding adequate view of the disc
  • 5\. Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., uncontrolled intraocular pressure, active eye infection, \<3 months post\- glaucoma filtering surgery, unstable medical status including blood pressure or glycemic control).
  • 6\.Participant is contraindicated for imaging by fundus imaging systems used in the study:
  • a.Participant is hypersensitive to light
  • b.Participant recently underwent photodynamic therapy (PDT)
  • c.Participant is photosensitive or is consuming medication that causes photosensitivity.

Outcomes

Primary Outcomes

Not specified

Similar Trials